Report cover image

Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 192 Pages
SKU # APRC20561637

Description

Summary

According to APO Research, The global Selective Serotonin Reuptake Inhibitors (SSRIs) market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Selective Serotonin Reuptake Inhibitors (SSRIs) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Selective Serotonin Reuptake Inhibitors (SSRIs) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Selective Serotonin Reuptake Inhibitors (SSRIs) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Selective Serotonin Reuptake Inhibitors (SSRIs) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Selective Serotonin Reuptake Inhibitors (SSRIs) include Allergan Plc, H. Lundbeck AS, GlaxoSmithKline Plc, Pfizer Inc. and Eli Lilly and Co., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Selective Serotonin Reuptake Inhibitors (SSRIs), market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Selective Serotonin Reuptake Inhibitors (SSRIs), also provides the revenue of main regions and countries. Of the upcoming market potential for Selective Serotonin Reuptake Inhibitors (SSRIs), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Selective Serotonin Reuptake Inhibitors (SSRIs) revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Selective Serotonin Reuptake Inhibitors (SSRIs) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Selective Serotonin Reuptake Inhibitors (SSRIs) revenue, projected growth trends, production technology, application and end-user industry.

Selective Serotonin Reuptake Inhibitors (SSRIs) Segment by Company

Allergan Plc
H. Lundbeck AS
GlaxoSmithKline Plc
Pfizer Inc.
Eli Lilly and Co.
Selective Serotonin Reuptake Inhibitors (SSRIs) Segment by Type

Citalopram (Celexa)
Sertraline (Zoloft)
Paroxetine (Paxil, Pexeva)
Fluoxetine (Prozac)
Vilazodone (Viibryd)
Escitalopram (Lexapro)
Selective Serotonin Reuptake Inhibitors (SSRIs) Segment by Application

Depression
Other mental conditions
Anxiety and panic disorder
Selective Serotonin Reuptake Inhibitors (SSRIs) Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Selective Serotonin Reuptake Inhibitors (SSRIs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Selective Serotonin Reuptake Inhibitors (SSRIs) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Selective Serotonin Reuptake Inhibitors (SSRIs).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Selective Serotonin Reuptake Inhibitors (SSRIs) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Selective Serotonin Reuptake Inhibitors (SSRIs) company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Selective Serotonin Reuptake Inhibitors (SSRIs) revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

192 Pages
1 Market Overview
1.1 Product Definition
1.2 Selective Serotonin Reuptake Inhibitors (SSRIs) Market by Type
1.2.1 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Citalopram (Celexa)
1.2.3 Sertraline (Zoloft)
1.2.4 Paroxetine (Paxil, Pexeva)
1.2.5 Fluoxetine (Prozac)
1.2.6 Vilazodone (Viibryd)
1.2.7 Escitalopram (Lexapro)
1.3 Selective Serotonin Reuptake Inhibitors (SSRIs) Market by Application
1.3.1 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Depression
1.3.3 Other mental conditions
1.3.4 Anxiety and panic disorder
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Selective Serotonin Reuptake Inhibitors (SSRIs) Market Dynamics
2.1 Selective Serotonin Reuptake Inhibitors (SSRIs) Industry Trends
2.2 Selective Serotonin Reuptake Inhibitors (SSRIs) Industry Drivers
2.3 Selective Serotonin Reuptake Inhibitors (SSRIs) Industry Opportunities and Challenges
2.4 Selective Serotonin Reuptake Inhibitors (SSRIs) Industry Restraints
3 Global Growth Perspective
3.1 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Perspective (2020-2031)
3.2 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Growth Trends by Region
3.2.1 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Region (2020-2025)
3.2.3 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Players
4.1.1 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Players (2020-2025)
4.1.2 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Market Share by Players (2020-2025)
4.1.3 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Key Players Headquarters & Area Served
4.4 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Players, Product Type & Application
4.5 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market CR5 and HHI
4.6.3 2024 Selective Serotonin Reuptake Inhibitors (SSRIs) Tier 1, Tier 2, and Tier 3
5 Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Type
5.1 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2020-2031)
5.3 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Market Share by Type (2020-2031)
6 Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Application
6.1 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2020-2031)
6.3 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 Allergan Plc
7.1.1 Allergan Plc Comapny Information
7.1.2 Allergan Plc Business Overview
7.1.3 Allergan Plc Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue and Gross Margin (2020-2025)
7.1.4 Allergan Plc Selective Serotonin Reuptake Inhibitors (SSRIs) Product Portfolio
7.1.5 Allergan Plc Recent Developments
7.2 H. Lundbeck AS
7.2.1 H. Lundbeck AS Comapny Information
7.2.2 H. Lundbeck AS Business Overview
7.2.3 H. Lundbeck AS Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue and Gross Margin (2020-2025)
7.2.4 H. Lundbeck AS Selective Serotonin Reuptake Inhibitors (SSRIs) Product Portfolio
7.2.5 H. Lundbeck AS Recent Developments
7.3 GlaxoSmithKline Plc
7.3.1 GlaxoSmithKline Plc Comapny Information
7.3.2 GlaxoSmithKline Plc Business Overview
7.3.3 GlaxoSmithKline Plc Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue and Gross Margin (2020-2025)
7.3.4 GlaxoSmithKline Plc Selective Serotonin Reuptake Inhibitors (SSRIs) Product Portfolio
7.3.5 GlaxoSmithKline Plc Recent Developments
7.4 Pfizer Inc.
7.4.1 Pfizer Inc. Comapny Information
7.4.2 Pfizer Inc. Business Overview
7.4.3 Pfizer Inc. Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue and Gross Margin (2020-2025)
7.4.4 Pfizer Inc. Selective Serotonin Reuptake Inhibitors (SSRIs) Product Portfolio
7.4.5 Pfizer Inc. Recent Developments
7.5 Eli Lilly and Co.
7.5.1 Eli Lilly and Co. Comapny Information
7.5.2 Eli Lilly and Co. Business Overview
7.5.3 Eli Lilly and Co. Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue and Gross Margin (2020-2025)
7.5.4 Eli Lilly and Co. Selective Serotonin Reuptake Inhibitors (SSRIs) Product Portfolio
7.5.5 Eli Lilly and Co. Recent Developments
8 North America
8.1 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue (2020-2031)
8.2 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2020-2031)
8.2.1 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2020-2025)
8.2.2 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2026-2031)
8.3 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Share by Type (2020-2031)
8.4 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2020-2031)
8.4.1 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2020-2025)
8.4.2 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2026-2031)
8.5 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Share by Application (2020-2031)
8.6 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country
8.6.1 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country (2020-2025)
8.6.3 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
8.6.6 Mexico
9 Europe
9.1 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue (2020-2031)
9.2 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2020-2031)
9.2.1 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2020-2025)
9.2.2 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2026-2031)
9.3 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Share by Type (2020-2031)
9.4 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2020-2031)
9.4.1 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2020-2025)
9.4.2 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2026-2031)
9.5 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Share by Application (2020-2031)
9.6 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country
9.6.1 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country (2020-2025)
9.6.3 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
9.6.9 Spain
9.6.10 Netherlands
9.6.11 Switzerland
9.6.12 Sweden
9.6.13 Poland
10 China
10.1 China Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue (2020-2031)
10.2 China Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2020-2031)
10.2.1 China Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2020-2025)
10.2.2 China Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2026-2031)
10.3 China Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Share by Type (2020-2031)
10.4 China Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2020-2031)
10.4.1 China Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2020-2025)
10.4.2 China Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2026-2031)
10.5 China Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue (2020-2031)
11.2 Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2020-2031)
11.2.1 Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2020-2025)
11.2.2 Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2026-2031)
11.3 Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Share by Type (2020-2031)
11.4 Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2020-2031)
11.4.1 Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2020-2025)
11.4.2 Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2026-2031)
11.5 Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Share by Application (2020-2031)
11.6 Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country
11.6.1 Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country (2020-2025)
11.6.3 Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue (2020-2031)
12.2 SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2020-2031)
12.2.1 SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2020-2025)
12.2.2 SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2026-2031)
12.3 SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Share by Type (2020-2031)
12.4 SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2020-2031)
12.4.1 SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2020-2025)
12.4.2 SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2026-2031)
12.5 SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Share by Application (2020-2031)
12.6 SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country
12.6.1 SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country (2020-2025)
12.6.3 SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.